Facebook
Twitter
LinkedIn
Forward
Mayo Clinic Pancreatic Cancer Conference 2016
Course Directors: Ramesh K. Ramanathan; Mitesh J. Borad, M.D.; Lynn M. Matrisian, Ph.D., the Pancreatic Cancer Action Network, and Daniel D. Von Hoff, M.D., F.A.C.P. (TGEN and Mayo Clinic)
Early-Bird rate extended to November 11, 2016!
This state-of-the-art conference, offered in cooperation with the Pancreatic Cancer Action Network, the Translational Genomics Research Institute (TGen) and Honor Health Research Institute, is designed to provide a multidisciplinary overview regarding the molecular biology of pancreatic cancer and the importance of early diagnosis and treatment considerations, including surgery, new pharmacological agents and how to incorporate these options into daily clinical practice. The program format will utilize case presentations, open Q&A and an interactive keypad system to generate participant feedback and develop an optimal learning experience between faculty and course participants.
This course is being offered in collaboration with TGEN, The Pancreatic Cancer Action Network and Honor Health.
Registration Fees
| Register on or before Nov. 11 | Register after Nov. 11 | |
| Full Fee: M.D., D.O., Scientist | $305.00 | $380.00 |
| Reduced Fee: Resident, Fellow, Nurse, NP, PA, Allied Health Professional | $230.00 | $305.00 |
Additional Information
Available Credit
Lodging and Accommodations
Course Brochure
Exhibitor Documents
Course Program
Exhibit Opportunity
This course offers the unique opportunity for commercial companies to interact with health care providers and highlight their products and services. If you are interested in exhibiting at this course, please complete the attached exhibit forms and submit to Kristy Badder
Target Audience
This course is designed for surgeons, gastroenterologists, radiation oncologists, medical oncologists, pain specialists, NPs, PAs and RNs.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify patients who will benefit from radiation therapy
- Incorporate novel agents in clinical care and clinical trial participation
- Explain palliative care management of the symptomatic patient
- Describe molecular biology of pancreatic cancer
- Describe the role of the PARP inhibitors and DNA damaging agents in the treatment of pancreatic cancer
- Select the appropriate regimen for first and second line therapy in treating advanced pancreatic cancer
- Describe the differences in staging between borderline and unresectable locally advanced pancreatic cancer
- Identify patients with resectable pancreatic cancer who are candidates for a minimally invasive procedure
- Explain the role of proton therapy and potential uses in pancreatic cancer
Attendance at this Mayo course does not indicate nor guarantee competence or proficiency in the performance of any procedures which may be discussed or taught in this course.
Available Credit
- 10.25 AMA PRA Category 1 Credit™
- 10.25 AOA